MedTrace Logo

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

NCT02756819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1945

Last updated 2019-11-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment in the Russian Federation and in the Republic of Kazakhstan..

Conditions

Interventions

DRUG

Azilsartan Medoxomil

Azilsartan medoxomil tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-18
Primary Completion
2018-05-08
Completion
2018-05-08
FDA Drug
Yes

Countries

  • Kazakhstan
  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756819 on ClinicalTrials.gov